Vijaypd Ceutical Limited Files for ₹19.25 Cr IPO on NSE Emerge; Aims to Fund API Manufacturing Plant
By Shishta Dutta | Published at: Jul 11, 2025 08:56 AM IST
Mumbai, July 10, 2025 — Vijaypd Ceutical Limited has filed its Draft Prospectus with NSE Emerge to raise ₹19.25 crore through a 100% fixed price IPO, targeting expansion into pharmaceutical manufacturing and debt reduction.
Vijaypd Ceutical Limited IPO Details
| Particulars | Details |
|---|---|
| Issue Size | ₹1,925.00 lakhs (Fresh Issue only) |
| Equity Shares Offered | 55,00,000 equity shares |
| Face Value | ₹10 per share |
| Issue Price | ₹35 per share |
| Lot Size | 4,000 shares |
| Market Maker Portion | 2,84,000 shares |
| Net Issue to Public | 52,16,000 shares |
| Post-Issue Share Capital | ₹1,952.87 lakhs |
| Listing Platform | NSE Emerge |
| Lead Manager | Smart Horizon Capital Advisors Pvt Ltd |
| Registrar | Kfin Technologies Ltd |
Use of Proceeds
The net proceeds from the IPO will be allocated as follows:
| Objective | Amount (₹ in lakhs) | % of Gross Proceeds |
|---|---|---|
| Capital Expenditure: API/intermediate plant at MIDC Shrirampur | 1,082.83 | 56.26% |
| Loan Repayment/Prepayment | 510.00 | 26.49% |
| General Corporate Purposes | To be finalized | To be finalized |
The proposed facility spans 6,000 square meters and will house production, QC, and utilities infrastructure. Estimated completion is targeted by March 2027.
Financial Highlights
| Particulars | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue from Operations | ₹11,709.79 lakh | ₹5,920.93 lakh | ₹5,109.39 lakh |
| Net Profit | ₹479.55 lakh | ₹165.02 lakh | ₹18.16 lakh |
| EBITDA Margin (%) | 7.34% | 8.22% | 2.58% |
| Net Worth | ₹3,216.98 lakh | ₹659.12 lakh | ₹493.15 lakh |
| Debt-Equity Ratio | 0.68x | 3.71x | 5.18x |
| ROE | 24.74% | 28.64% | 3.96% |
The company has shown consistent growth, especially in FY25, supported by scale expansion and margin improvement.
Shareholding Pattern
| Shareholders | Pre-Issue Holding (%) | Post-Issue Holding (%) |
|---|---|---|
| Promoters | 71.76% | 51.55% |
| Promoter Group | 10.11% | 7.26% |
| Public | 18.13% | 41.19% |
The promoter group includes Samit Madhukar Shah, Bhavin Dhirendra Shah, and others. A total of 39.25 lakh shares will be locked in for three years as part of promoter contribution.
Strategic Outlook
The IPO aims to reduce external debt (₹510 lakh repayment planned) and fund a manufacturing facility to enter the API and intermediate space—capitalizing on India’s push for self-reliance in pharma raw materials under PLI schemes. The company also expects cost efficiencies and improved supply control through backward integration.
About the Company
Vijaypd Ceutical Limited, originally a partnership firm established in 1971 as Vijay Pharma, operates as a distributor and stockist in the pharmaceutical and FMCG sectors. The firm converted into a public company in March 2024. It currently distributes pharmaceuticals, diagnostics, and wellness products, and now plans to diversify into manufacturing APIs, intermediates, and excipients from its proposed Ahmednagar unit.
It is a registered company under CIN: U21001MH2024PLC421713 and proposes to list on NSE Emerge under Regulation 229(2) and 253(3) of SEBI ICDR Regulations.
REF: https://nsearchives.nseindia.com/emerge/corporates/content/sezalm_10072025172607_1DraftProspectusVijaypd.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
